ACADIA PHARMACEUTICALS INC. Proceeds from Stock Options Exercised
ACADIA PHARMACEUTICALS INC. (ACAD) reported Proceeds from Stock Options Exercised of $20.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-02-28
- ACADIA PHARMACEUTICALS INC. proceeds from stock options exercised for fiscal 2023 was $20.30M, a 448.65% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. proceeds from stock options exercised for fiscal 2022 was $3.70M, a 71.32% decline from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. proceeds from stock options exercised for fiscal 2021 was $12.90M, a 82.52% decline from fiscal 2020.
- ACADIA PHARMACEUTICALS INC. proceeds from stock options exercised for fiscal 2020 was $73.80M, a 23.12% decline from fiscal 2019.
| Period end | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|
| 2023-12-31 | $20.30M 10-K · filed 2024-02-28 | |
| 2022-12-31 | $3.70M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $12.90M 10-K · filed 2024-02-28 | $12.90K 10-K · filed 2022-03-01 |
| 2020-12-31 | $73.80M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $96.00M 10-K · filed 2020-02-27 | |
| 2018-12-31 | $4.40M 10-K · filed 2019-02-27 | |
| 2017-12-31 | $26.70M 10-K · filed 2018-02-27 | |
| 2016-12-31 | $18.00M 10-K · filed 2017-02-28 | |
| 2015-12-31 | $13.00M 10-K · filed 2016-02-29 | |
| 2014-12-31 | $6.40M 10-K · filed 2015-02-26 | |
| 2013-12-31 | $3.40M 10-K · filed 2014-02-27 | |
| 2012-12-31 | $453.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |